Intermediate results of the PERFECTION observational study in a population of patients with metastatic, persistent and recurrent cervical cancer
Journal: Journal of Modern Oncology
Year: 2025

Background. Cervical cancer (CC) is among the four most common malignancies among the female population. For a long time, platinum-based chemotherapy was the standard of care and practically the only option available. However, treatment outcomes for patients with metastatic and recurrent CC remained poor. The use of immune checkpoint inhibitors significantly increased progression-free survival and overall survival in this group of patients. Currently, pembrolizumab is a priority option in treati